Literature DB >> 1605091

Sex hormone binding and peritumoural oedema in meningiomas: is there a correlation?

J Meixensberger1, H Caffier, M Naumann, E Hofmann.   

Abstract

Steroid receptor binding activity was evaluated in specimens of 28 human cerebral meningiomas using a dextran coated charcoal (DCC) assay. Oestrogen receptor (ER) binding activity at significant levels (greater than 10 fmol/mg protein) could be detected only in three postmenopausal females (11% positive cases) at low levels. Positive progesterone receptor (PR) binding was detected in eighteen of the twenty-eight analysed meningioma tissues (64% positive cases). A significantly higher level of PR in male than in female patients could be demonstrated. The degree of peritumoural oedema could be evaluated from CT scans. There was no significant correlation between lack and amount of peritumoural oedema and quantity of cytosolic PR binding activity. Therefore we conclude, that peritumoural oedema is related to other factors and a possible role of PR activity in development of peritumoural oedema and growth control of meningiomas could not be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1605091     DOI: 10.1007/bf01406365

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  36 in total

1.  The prediction of recurrence in meningiomas.

Authors:  M R Crompton; P C Gautier-Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-02       Impact factor: 10.154

2.  Computerized tomography scanning appearances of intracranial meningiomas. An attempt to predict the histological features.

Authors:  J Vassilouthis; J Ambrose
Journal:  J Neurosurg       Date:  1979-03       Impact factor: 5.115

3.  New embolization method using estrogen: effect of estrogen on microcirculation.

Authors:  Y Nagamine; S Komatsu; J Suzuki
Journal:  Surg Neurol       Date:  1983-10

4.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

5.  Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor.

Authors:  K B Horwitz; W L McGuire
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

6.  The vascular component in meningiomas associated with severe cerebral edema.

Authors:  V R Challa; D M Moody; R B Marshall; D L Kelly
Journal:  Neurosurgery       Date:  1980-10       Impact factor: 4.654

7.  Correlation between sex hormone binding and peritumoral edema in intracranial meningiomas.

Authors:  E C Benzel; F B Gelder
Journal:  Neurosurgery       Date:  1988-08       Impact factor: 4.654

8.  Estrogen-receptor protein in intracranial meningiomas.

Authors:  M S Donnell; G A Meyer; W L Donegan
Journal:  J Neurosurg       Date:  1979-04       Impact factor: 5.115

9.  Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features.

Authors:  T M Markwalder; D T Zava; A Goldhirsch; R V Markwalder
Journal:  Surg Neurol       Date:  1983-07

10.  Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling.

Authors:  K G Cho; T Hoshino; T Nagashima; J A Murovic; C B Wilson
Journal:  J Neurosurg       Date:  1986-12       Impact factor: 5.115

View more
  2 in total

1.  Brain oedema in patients with intracranial meningioma. Correlation between clinical, radiological, and histological factors and the presence and intensity of oedema.

Authors:  R D Lobato; R Alday; P A Gómez; J J Rivas; J Domínguez; A Cabrera; S Madero; J Ayerbe
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

2.  Cerebral edema associated with meningiomas: the role of peritumoral brain tissue.

Authors:  R Vaz; N Borges; C Cruz; I Azevedo
Journal:  J Neurooncol       Date:  1998-02       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.